keyword
MENU ▼
Read by QxMD icon Read
search

Xeomin

keyword
https://www.readbyqxmd.com/read/29408357/evidence-on-botulinum-toxin-in-selected-disorders
#1
Elina Zakin, David Simpson
Botulinum toxin (BoNT) is a neurotoxin produced by the bacteria Clostridium botulinum that has become widely used for various neurologic indications. The four toxin formulations currently available for use in the United States (approved by the Food and Drug Administration) are onabotulinumtoxinA (Botox® ), abobotulinumtoxinA (Dysport® ), incobotulinumtoxinA (Xeomin® ), and rimabotulinumtoxinB (Myobloc® ). While the FDA-approved labels indicate that potency conversions should not be done, literature supports relative dose equivalents of approximately 1:1:2-4:50-100, respectively...
February 3, 2018: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/29382036/botulinum-toxin-a-for-sialorrhoea-associated-with-neurological-disorders-evaluation-of-the-relationship-between-effect-of-treatment-and-the-number-of-glands-treated
#2
Domenico A Restivo, Mariangela Panebianco, Antonino Casabona, Sara Lanza, Rosario Marchese-Ragona, Francesco Patti, Stefano Masiero, Antonio Biondi, Angelo Quartarone
Background: Sialorrhoea and drooling are disabling manifestations of different neurological disorders. The aim of this study was to evaluate the effects of botulinum neurotoxin type A (BoNT/A) injection on hypersalivation in 90 patients with neurological diseases of different aetiologies, and to define the minimum number of injected salivary glands to reduce sialorrhoea. Determining the minimum number of glands that need to be engaged in order to have a significant reduction in drooling may be very useful for establishing the minimum total dosage of BoNT/A that may be considered effective in the treatment of hypersalivation...
January 27, 2018: Toxins
https://www.readbyqxmd.com/read/29230798/botulinum-toxin-type-a-therapy-for-cervical-dystonia
#3
REVIEW
Mafalda Castelão, Raquel E Marques, Gonçalo S Duarte, Filipe B Rodrigues, Joaquim Ferreira, Cristina Sampaio, Austen P Moore, João Costa
BACKGROUND: This is an update of a Cochrane Review first published in 2005. Cervical dystonia is the most common form of focal dystonia and is a highly disabling movement disorder characterised by involuntary, usually painful, head posturing. Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition. OBJECTIVES: To compare the efficacy, safety, and tolerability of botulinum toxin type A (BtA) versus placebo in people with cervical dystonia...
December 12, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29102441/incobotulinum-toxin-a-in-parkinson-s-disease-with-foot-dystonia-a%C3%A2-double-blind-randomized-trial
#4
Isabelle Rieu, Bertrand Degos, Giovanni Castelnovo, Christophe Vial, Elodie Durand, Bruno Pereira, Marion Simonetta-Moreau, Sophie Sangla, Frédérique Fluchère, Dominique Guehl, Pierre Burbaud, Christian Geny, Dominique Gayraud, Fabienne Ory-Magne, Françoise Bouhour, Elisabeth Llinares, Philippe Derost, Ana Marques, Franck Durif
INTRODUCTION: Plantar flexion of toe dystonia is very painful and leads to difficulties in walking. The objective of this study was to investigate the effect of incobotulinum toxin A (Xeomin) in the treatment of this type of dystonia in parkinsonian patients, using a randomized, double blind, placebo-controlled trial. METHODS: 45 parkinsonian patients with painful dystonic plantar flexion of toes were injected either with incobotulinum toxin A (Btx group), or with placebo in two muscle targets: the Flexor digitorum longus and the Flexor digitorum brevis...
October 19, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/29053134/-conversion-ratio-between-different-botulinum-neuroprotein-product-in-neurological-practice
#5
O R Orlova, S L Timerbaeva, S E Khatkova, E V Kostenko, D A Krasavina, D V Zakharov
Despite nearly 30 years of experience in the application of botulinum toxin type A (BTA) in clinical practice, many fundamental questions of therapy remain valid. There are 5 botulinum toxin type A used for neurological indications in the Russian Federation in 2017. They contain different number of active neuroprotein (150 kDa) in a therapeutic dose of the drug that may have a potential impact on the efficacy and duration of action. The current SmPC of each BTA stated that the unit of activity is unique and can not be compared with any other BTA...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28915291/cosmetic-practitioners-take-huge-risks-purchasing-and-administering-illegal-botulinum-toxin-drug-products
#6
Sheldon Bradshaw
In their article "Importing Injectables" in the September 2014 issue of the Journal of Drugs in Dermatology, Dr. Kenneth Beer and Karen Rothschild highlighted the possible harm to patients and practitioners from the use of unapproved botulinum toxin products - eg, Botox, Dysport, Xeomin, and Myobloc - and other cosmetic prescription drug products purchased from foreign or unlicensed suppliers.1 In the intervening years, the accuracy of their critique has been repeatedly demonstrated, as the dangers to patients' health, as well as to cosmetic practitioners' liberty, has only increased...
September 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28657917/patient-registry-of-spasticity-care-world-data-analysis-based-on-physician-experience
#7
Alberto Esquenazi, Stella Lee, Nathaniel Mayer, Roser Garreta, Atul Patel, Elie Elovic, Stephen Koelbel, Gerard Francisco, Iris Reuter
OBJECTIVE: The aim of the study was to report physician experience-based "real-world" treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury. DESIGN: A prospective, multicenter, international observational registry design was used. RESULTS: Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians...
December 2017: American Journal of Physical Medicine & Rehabilitation
https://www.readbyqxmd.com/read/28639368/botulinum-toxin-state-of-the-art
#8
REVIEW
Joseph Jankovic
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions...
August 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28440002/differential-effect-of-incobotulinumtoxin-a-on-pain-neurogenic-flare-and-hyperalgesia-in-human-surrogate-models-of-neurogenic-pain
#9
S A Diener, M Breimhorst, Th Vogt, H H Krämer, P D Drummond, C Geber, F Birklein
BACKGROUND: The effectiveness of Botulinum-neurotoxin A (BoNT/A) to treat pain in human pain models is very divergent. This study was conducted to clarify if the pain models or the route of BoNT/A application might be responsible for these divergent findings. METHODS: Sixteen healthy subjects (8 males, mean age 27 ± 5 years) were included in a first set of experiments consisting of three visits: (1) Visit: Quantitative sensory testing (QST) was performed before and after intradermal capsaicin injection (CAPS, 15 μg) on one thigh and electrical current stimulation (ES, 1 Hz) on the contralateral thigh...
April 25, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/28290229/incobotulinumtoxina-injection-for-temporomandibular-joint-disorder
#10
RANDOMIZED CONTROLLED TRIAL
Amit A Patel, Michael Z Lerner, Andrew Blitzer
OBJECTIVES: Temporomandibular disorder (TMD) involves dysfunction of the temporomandibular joint and associated muscles of mastication causing pain with chewing, limitation of jaw movement, and pain. While the exact pathophysiology of TMD is not completely understood, it is thought that hyperfunction of the muscles of mastication places stress on the temporomandibular joint, leading to degeneration of the joint and associated symptoms. We hypothesize that chemodenervation of the muscles of mastication with IncobotulinumtoxinA (Xeomin) will decrease the stress on the temporomandibular joint and improve pain associated with temporomandibular joint and muscle disorder (TMJD)...
April 2017: Annals of Otology, Rhinology, and Laryngology
https://www.readbyqxmd.com/read/28283596/safety-and-efficacy-of-incobotulinumtoxina-doses-up-to-800-u-in-limb-spasticity-the-tower-study
#11
MULTICENTER STUDY
Jörg Wissel, Djamel Bensmail, Joaquim J Ferreira, Franco Molteni, Lalith Satkunam, Susana Moraleda, Tiina Rekand, John McGuire, Astrid Scheschonka, Birgit Flatau-Baqué, Olivier Simon, Edward T J Rochford, Dirk Dressler, David M Simpson
OBJECTIVE: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity. METHODS: In this prospective, single-arm, dose-titration study (NCT01603459), patients (18-80 years) with spasticity due to cerebral causes, who were clinically deemed to require total doses of 800 U incobotulinumtoxinA, received 3 consecutive injection cycles (ICs) with 400 U, 600 U, and 600-800 U incobotulinumtoxinA, respectively, each followed by 12-16 weeks' observation...
April 4, 2017: Neurology
https://www.readbyqxmd.com/read/28253424/botulinum-toxin-for-the-treatment-of-strabismus
#12
REVIEW
Fiona J Rowe, Carmel P Noonan
BACKGROUND: The use of botulinum toxin as an investigative and treatment modality for strabismus is well reported in the medical literature. However, it is unclear how effective it is in comparison to other treatment options for strabismus. OBJECTIVES: The primary objective was to examine the efficacy of botulinum toxin therapy in the treatment of strabismus compared with alternative conservative or surgical treatment options. This review sought to ascertain those types of strabismus that particularly benefit from the use of botulinum toxin as a treatment option (such as small angle strabismus or strabismus with binocular potential, i...
March 2, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27747444/safety-of-botulinum-toxin-short-interval-therapy-using-incobotulinumtoxin-a
#13
Dirk Dressler, Fereshte Adib Saberi
The therapeutic efficacy of botulinum toxin (BT) can be completely blocked by formation of BT antibodies (BTAB), thus producing antibody-induced therapy failure (ABTF). One of the risk factors for this is the interval between two subsequent injection series. To prevent BTAB formation it is universally recommended not to use interinjection intervals of less than 12 weeks. However, BT's therapeutic efficacy may be considerably shorter than this interval, thus causing substantial reduction of quality of life...
April 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/27676911/therapeutic-benefit-of-botulinum-toxin-a-for-the-spasticity-of-the-triceps-surae-in-patients-with-multiple-sclerosis-an-observational-study
#14
Philippe Gallien, Benoit Nicolas, Leblong Emilie, Sabine Petrilli, Sandrine Robineau, Aurelie Durufle, Katell Autret, Tiphaine Berthier, Lucie Chochina, Bastien Fraudet, Corinne Pfeiffer
INTRODUCTION: Few data are available on the use of botulinum toxin for spasticity treatment in multiple sclerosis. In a previous study, we found that one of the main therapeutic goals was the improvement ok walking, in patients suffering from spasticity of the triceps surae. OBJECTIVE: This is a pilot observational study, with the aim to assess the benefit of an injection of 200 UI of incobotulinumtoxin A in multiple sclerosis patients suffering from spasticity du triceps surae...
September 2016: Annals of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/27673516/advancements-and-refinement-in-facial-neuromodulators
#15
Reza Kordestani, Kevin H Small, Rod J Rohrich
The use of neuromodulators has increased by approximately 748 percent from 2000 to 2014 and has become an integral adjunct for facial rejuvenation. Knowledge of facial anatomy, accurate facial analysis, and familiarity with neurotoxin characteristics will minimize complications and optimize results. Current U.S. Food and Drug Administration-approved neurotoxins in the United States include onabotulinumtoxin A (Botox), abobotulinumtoxin A (Dysport), and incobotulinumtoxin A (Xeomin). The dosage and effect of these products are not interchangeable, so practitioners should master the utility and response of one product before trying the other products...
October 2016: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/27633917/gender-differences-in-onabotulinum-toxin-a-dosing-for-adductor-spasmodic-dysphonia
#16
Michael Z Lerner, Benjamin A Lerner, Amit A Patel, Andrew Blitzer
OBJECTIVES/HYPOTHESIS: The objective of this study was to determine the influence of gender on onabotulinum toxin A dosing for the treatment of adductor spasmodic dysphonia symptoms. STUDY DESIGN: Retrospective review. METHODS: A chart review of the senior author's database of botulinum toxin injections was performed. Patients diagnosed with adductor spasmodic dysphonia who received onabotulinum toxin A (BoNTA) injections to the thyroarytenoid muscle for at least 5 years were included for study...
May 2017: Laryngoscope
https://www.readbyqxmd.com/read/27530616/incobotulinumtoxina-a-review-in-upper-limb-spasticity
#17
REVIEW
Yvette N Lamb, Lesley J Scott
Intramuscular incobotulinumtoxinA (Xeomin(®)) is indicated for the treatment or improvement of adult patients with upper limb spasticity (featured indication), cervical dystonia, blepharospasm and glabellar lines. It is a highly purified formulation of botulinum toxin type A that inhibits acetylcholine signalling at neuromuscular junctions, reducing muscle hypertonia. This narrative review discusses the clinical use of incobotulinumtoxinA in adults with upper limb spasticity and summarizes its pharmacological properties...
September 2016: Drugs
https://www.readbyqxmd.com/read/27461432/impact-of-botulinum-toxin-a-injection-on-esophageal-anastomosis-in-a-rabbit-model
#18
Yoshiko Usui, Shigeru Ono
PURPOSE: The management of esophageal atresia is established, but the rate of postoperative complications remains high. We focused on a new, recently reported method of esophageal elongation using botulinum toxin type A (BTX-A) and evaluated the efficacy of BTX-A injection around esophageal anastomoses with tension in a rabbit model. METHODS: Twenty rabbits aged 8-10 weeks and weighing 1.27-1.72 kg underwent resections of the esophagus measuring 1.5 cm long using an anterior cervical approach...
September 2016: Pediatric Surgery International
https://www.readbyqxmd.com/read/27363760/overview-of-botulinum-toxins-for-aesthetic-uses
#19
REVIEW
Michael S Gart, Karol A Gutowski
Botulinum toxin type A (BTA) can be used for facial aesthetics. The 3 currently available BTA types include onabotulinumtoxinA (Botox; Botox Cosmetic, Allergan, Irvine, CA), abobotulinumtoxinA (Dysport; Ipsen, Ltd, Berkshire, UK), and incobotulinumtoxinA (Xeomin; Merz Pharmaceuticals, Frankfurt, Germany). The mechanism of action and clinical uses for treatment of dynamic lines of the forehead, brow, glabella, lateral orbit, nose, and lips are presented, as well as treatment of masseter hypertrophy, platysmal bands, and improvements of the perioral region...
July 2016: Clinics in Plastic Surgery
https://www.readbyqxmd.com/read/27177451/safety-profile-of-incobotulinum-toxin-a-xeomin-%C3%A2-in-gastrocnemious-muscles-injections-in-children-with-cerebral-palsy-randomized-double-blind-clinical-trial
#20
RANDOMIZED CONTROLLED TRIAL
Elena Carraro, Enrico Trevisi, Andrea Martinuzzi
BACKGROUND: The only two preparations of botulinum toxin A for which there are published evidences of efficacy in children with cerebral palsy are onabotulinum toxin A (Botox(®)) and abobotulinum toxin A (Dyport(®)); these toxins should be considered generally safe and appropriate in the treatment for localized upper and lower limb spasticity. AIMS: To establish the safety profile of incobotulinum toxin A (Xeomin(®)) in children with cerebral palsy and muscle spasticity...
July 2016: European Journal of Paediatric Neurology: EJPN
keyword
keyword
9456
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"